Studies reveal a small number of people developed symptoms associated with Guillain-Barre syndrome following the Astra-Zeneca COVID-19 vaccine. As with all vaccines, while a tiny percentage of people may develop adverse side effects, it is still vital that people continue to get vaccinated against COVID.
A number of videos have surfaced on popular channels showing people experiencing some adverse effects following the coronavirus vaccine. Researchers say some of the cases could be related to functional neurological disorder, a common neuropsychological condition.
Constant exposure to images of syringes and people getting the COVID-19 vaccine on TV and social media may discourage those with phobias of needles from getting their shots, researchers report.
A COVID-19 vaccine under trial in the UK is safe, has few side effects, and induces a strong immune response in both parts of the immune system within 14 days of administration.
Researchers have developed a new vaccine that fully protects mice against MERS by using a harmless virus to deliver MERS-CoV into cells and generate an immune response. The vaccine is an innocuous parainfluenza virus (PIV5) which carries the spike protein MERS uses to infect cells. Findings show the PIV5 based vaccine could be a useful platform for COVID-19.
A new COVID-19 vaccine produces antibodies specific to SARS-CoV-2 at quantities believed sufficient for neutralizing the virus, a mouse model study reveals. The new vaccine using an innovative microneedle array on fingertip-sized pads, which increases the vaccine potency.
Intermittent social distancing may have to be employed to reduce the burden on the health care system as a result of COVID-19. If COVID-19 is a seasonal ailment, like the flu, a new model shows physical distancing occurring between 25 and 75% of the time would help build up herd immunity and prevent health system overload.
VPM1002, a vaccine candidate based on the tuberculosis BCG vaccine, may be effective in protecting against COVID-19. Previous studies in mice have shown the BCG vaccine is effective at protecting against several respiratory viral infections. If effective against coronavirus, researchers hope the vaccine can bridge the time gap until a specific SARS-CoV-2 vaccine is available.
Researchers report they have identified a vaccine candidate for COVID-19 and are working towards phase one clinical testing. A chimpanzee adenovirus vaccine vector was chosen as the most suitable vaccine technology for SARS-CoV-2 as it can generate a stronger immune response in one dose and is not a replicating virus.
Researchers are making progress in developing potential vaccines for coronavirus infections. While a vaccine for COVID-19 might be over a year away from market, researchers are looking ahead to attempt to prevent future outbreaks.
With the peak of COVID-19 cases occurring between 3.5 to four weeks after controlled interventions were put into place in China, US researchers are urging the public to ramp up social distancing efforts and increase testing immediately.
A phase 1 trial evaluating an investigational vaccine designed to protect against COVID-19 has begun in Seattle. The study will enroll 45 healthy people aged 18 to 55, over approximately 6 weeks. The first participant received the investigational vaccine today. Adults in the Seattle area may join the study.